Medical incubator ForSight Labs has launched glaucoma treatment company, Transcend Medical, with a $7 million in a first round of funding from venture capitalists, according to VentureWire (sub required).

Morgenthaler Ventures and Split Rock Partners, two of the investors in ForSight, co-led the round. ForSight’s third investor, Versant Ventures, did not participate because it already has another glaucoma treatment company, Glaukos Corp., in its portfolio, Campbell told VentureWire. Morgenthaler, Split Rock and Versant participated in an earlier $2.4 million financing for Transcend, said Robin Bellas, general partner at Morgenthaler.